Clinical Research Study for Individuals with Parkinson’s Disease (PD) Who are Currently Experiencing Inadequately Controlled Depression
|Purpose||The primary objective of this multi-center, open-label study is to assess the effectiveness and safety of the investigational study drug Pimavanserin in individuals with Parkinson’s disease (PD) who have depression that is not adequately controlled by their current antidepressant.|
|Summary||According to the National Parkinson Foundation, about one million people in the United States suffer from Parkinson’s disease (PD). Parkinson’s disease is a progressive neurodegenerative disorder characterized primarily by motor deficits; however, there are also associated behavioral symptoms that are frequent, severe, and disabling. Mood disorders and, in particular, depression occur in approximately 50% of individuals with PD. Symptoms of depression in Parkinson’s disease are associated with increased morbidity and diminished quality of life. Conversely, improved depression is associated with reduced physical disability and improved quality of life.
The management of PD related depression represents a major unmet need in PD. Pimavanserin is an investigational new drug being evaluated by ACADIA Pharmaceuticals for inadequately controlled depression in adults with Parkinson’s disease.
|Diagnosis and Main Criteria
|Individuals diagnosed with Parkinson’s disease who have depression that is not adequately controlled by their current antidepressant medication.|
|Duration of Treatment
||If you qualify and participate in this study, you will need to visit the research study site for an initial screening and 5 more times within an 8-week period. There will also be a telephone follow-up call 2 weeks after your last dose of investigational study drug.|
||To see if you qualify to participate in this trial you may click the link below to complete the online pre-screening form or call us toll-free at 877-547-8839. Please Note – you must be registered or logged in to take the questionnaire
We look forward to speaking with you.